Considering favorable efficacy in immune checkpoint inhibitors (especially PD‐1/PD‐L1 inhibitors) achieved in treating cervical cancer,40 our study also assessed the expression status of CTLA4, PD‐1, and PD‐L1 in cervical cancer patients grouped by different expression of HOXA1, HOXA10, and HOXA11. The gene discussed is HOXA10; the disease is cervical carcinoma.